Tejnaksh Healthcare

20.80
-0.23
(-1.09%)
Market Cap
42.23 Cr
EPS
0.87
PE Ratio
18.61
Dividend Yield
0.00 %
52 Week High
30.50
52 Week Low
20.71
PB Ratio
1.72
Debt to Equity
0.25
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
2,478.80
#1 20,720.72
50.13
#1 2,295.80
11.52
#1 362
19.34
43.44
1,007.20
10,337.53
72.42
568.60
20.11
120
35.77
47.60
1,564.55
8,023.19
53.44
1,216.80
4.59
129
15.38
34.43
679.65
3,601.70
42.34
581.30
8.63
70
29.25
36.44
787.90
2,544.11
34.57
636.40
25.65
57
49.23
52.38
1,616.75
1,387.61
29.87
86.70
25.47
32
58.82
37.91
242.42
771.15
#1 7.43
1,436.10
35.04
6
-1,081.25
49.93
369.90
262.59
21.80
63.00
#1 248.07
7
133.33
75.20
85.23
87.69
109.40
13.60
-8.11
-3
#1 142.86
51.49
120.15
83.73
66.60
36.90
6.34
1
0.00
43.10
Growth Rate
Revenue Growth
4.17 %
Net Income Growth
-
Cash Flow Change
98.58 %
ROE
-8.76 %
ROCE
-3.98 %
EBITDA Margin (Avg.)
-5.24 %

Quarterly Financial Results

Quarterly Financials
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
6
6
5
5
5
4
2
3
3
4
3
4
3
3
3
4
3
3
3
3
3
3
3
4
3
Expenses
4
4
3
3
3
3
1
2
3
2
2
2
2
2
2
2
2
2
3
2
2
2
2
2
2
EBITDA
1
2
1
1
1
0
0
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
Operating Profit %
17 %
28 %
29 %
25 %
23 %
8 %
24 %
34 %
28 %
34 %
38 %
37 %
39 %
37 %
38 %
43 %
27 %
14 %
17 %
37 %
34 %
31 %
34 %
34 %
36 %
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
1
2
1
1
1
0
0
1
1
1
1
1
1
1
1
1
0
0
0
1
1
1
1
1
1
Tax
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Net Profit
1
1
1
1
1
-0
0
1
1
1
1
1
1
1
1
1
0
0
0
1
1
1
1
1
1
EPS in ₹
0.61
1.21
0.73
0.81
0.58
-0.05
0.07
0.57
0.60
0.77
0.75
0.73
0.67
0.53
0.55
0.82
0.31
-0.01
0.08
0.28
0.27
0.25
0.29
0.31
0.38

Balance Sheet

Balance Sheet
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
7
16
20
22
25
25
30
31
31
Fixed Assets
3
14
15
17
17
15
15
23
23
Current Assets
1
2
3
5
7
3
5
6
6
Capital Work in Progress
0
0
0
0
1
1
9
1
1
Investments
0
0
0
0
0
0
0
0
0
Other Assets
4
2
4
5
7
9
5
7
7
Total Liabilities
7
16
20
22
25
25
30
31
31
Current Liabilities
0
1
3
2
2
2
2
2
2
Non Current Liabilities
0
7
6
6
8
5
7
7
6
Total Equity
6
8
10
14
16
18
21
22
24
Reserve & Surplus
5
6
8
3
5
7
10
12
13
Share Capital
1
2
2
10
10
10
10
10
10

Cash Flow

Cash Flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
0
1
1
-1
0
-0
0
-1
1
Investing Activities
-3
-8
-3
-2
-1
2
-11
-1
-1
Operating Activities
4
2
5
3
1
1
9
2
4
Financing Activities
-0
6
-1
-2
0
-3
2
-1
-2

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
73.84 %
73.84 %
73.84 %
73.83 %
73.83 %
73.83 %
73.83 %
73.83 %
73.83 %
73.83 %
73.83 %
73.83 %
73.83 %
73.83 %
73.83 %
73.83 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.58 %
0.58 %
0.28 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
23.43 %
23.19 %
23.01 %
22.58 %
23.04 %
23.29 %
22.27 %
23.83 %
22.72 %
22.75 %
23.00 %
22.83 %
22.21 %
23.49 %
23.84 %
23.65 %
Others
2.73 %
2.97 %
3.15 %
3.59 %
3.13 %
2.88 %
3.90 %
2.34 %
3.45 %
3.42 %
2.58 %
2.75 %
3.68 %
2.68 %
2.33 %
2.52 %
No of Share Holders
732
908
990
974
998
967
994
1,041
1,445
1,636
2,628
3,057
3,502
3,776
4,067
4,496

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Closure of Trading Window5 days ago
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportFeb 24, 2025
Shareholder Meeting / Postal Ballot-Outcome of EGMFeb 22, 2025
Integrated Filing (Financial)Feb 12, 2025
Submission Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended On 31St December 2024.Feb 11, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On 11Th February 2025 Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 11, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations 2015 And Closure Of Trading WindowFeb 03, 2025
Extra Ordinary General Meeting (EOGM) Of The Members Of Tejnaksh Healthcare Limited Is Scheduled To Be Held On Saturday The 22Nd February 2025 At 3.00 Pm (IST) Through Two-Way Video Conferencing (VC) Jan 30, 2025
Announcement under Regulation 30 (LODR)-Raising of FundsJan 24, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On 23Rd January 2025 Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 23, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 19, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations 2015Jan 17, 2025
Closure of Trading WindowDec 16, 2024
Announcement Of Indian Patent Grant For Pflow - A Milestone Achievement By Dr. Ashish Rawandale PatilDec 16, 2024
Submission Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended On 30Th September 2024.Nov 14, 2024
Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations AndDisclosure Requirements) Regulations, 2015Nov 14, 2024
Board Meeting Intimation for Regulation 29 Of SEBI (LODR) Regulations, 2015 And ClosureOf Trading WindowNov 07, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 20, 2024
Announcement Of Dr. Ashish Rawandale'S Appointment As President Of The Urological Society OfIndia Under Regulation 30Oct 13, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 28, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 28, 2024
Closure of Trading WindowSep 26, 2024
Announcement Under Regulation 30 - Participation Of Dr. Ashish Rawandale In The Arab Association Of Urology EventSep 19, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2024
Intimation Of Book Closure And E-Voting Of The 17Th Annual General Meeting Of The CompanyAug 31, 2024
Reg. 34 (1) Annual Report.Aug 31, 2024
Notice Of 17Th Annual General Meeting Of The Company To Be Held On 28Th September 2024Aug 31, 2024
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sAug 14, 2024
Announcement under Regulation 30 (LODR)-Resignation of Statutory AuditorsAug 14, 2024
Submission Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended On 30Th June 2024.Aug 14, 2024
Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations And DisclosureRequirements) Regulations, 2015Aug 14, 2024
Board Meeting Intimation for Regulation 29 Of SEBI (LODR) Regulations, 2015 And ClosureOf Trading WindowAug 06, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 19, 2024
Closure of Trading WindowJun 29, 2024
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2024
Submission Of Audited Financial Results (Standalone & Consolidated) For The Quarter Ended And Year End On 31Th March, 2024.May 28, 2024
Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations AndDisclosure Requirements) Regulations, 2015 And Disclosure Pursuant To Regulation 30May 28, 2024
Board Meeting Intimation for Regulation 29 SEBI Regulation 2015May 17, 2024
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2Apr 19, 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 19, 2024
Yearly Compliance Certificate (Financial Year Ended On March 31St, 2024Apr 17, 2024
Submission Of Certificate Under Regulation 7(3) Of SEBI (LODR) Regulation, 2015 For The Year Ended On 31.03.2024Apr 16, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Apr 15, 2024
Closure of Trading WindowMar 26, 2024
Submission Of Un-Audited Financial Results (Standalone & Consolidated) For The QuarterEnded On 31St December 2023.Feb 12, 2024
Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations And DisclosureRequirements) Regulations, 2015Feb 12, 2024
Board Meeting Intimation for Regulation 29 Of SEBI (LODR) Regulations, 2015 And ClosureOf Trading WindowFeb 05, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jan 19, 2024
Announcement Under Regulation 30 --Incredible Achievement In Urology InnovationJan 01, 2024
Closure of Trading WindowDec 30, 2023

Technical Indicators

RSI(14)
Neutral
31.68
ATR(14)
Less Volatile
1.37
STOCH(9,6)
Neutral
25.79
STOCH RSI(14)
Oversold
0.00
MACD(12,26)
Bearish
-0.13
ADX(14)
Strong Trend
29.61
UO(9)
Bullish
25.42
ROC(12)
Downtrend And Accelerating
-8.62
WillR(14)
Oversold
-92.88